Cardio Diagnostics Launches Blood Test for Early Detection of Coronary Heart Disease

 PrecisionCHD™ is the First Integrated Epigenetic-Genetic-Based Blood Test for the Early Detection of Coronary Heart Disease

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.

PrecisionCHD is the second clinical test built using Cardio Diagnostics’ proprietary AI-driven Integrated Epigenetic-Genetic Engine. The company’s initial product, Epi+Gen CHD™, a three-year coronary heart disease risk assessment test, also leveraged the Engine and was launched in 2021. The two tests address the most common form of cardiovascular disease – coronary heart disease – across the entire spectrum, from assessing risk for prevention to early detection. Over the next two years, Cardio Diagnostics expects to continue to leverage its Engine to develop a series of integrated epigenetic-genetic clinical tests for other cardiovascular diseases and associated conditions.

Cardiovascular disease (CVD) continues to be the leading cause of death in the United States, with coronary heart disease (CHD) being the most common type of CVD and the primary cause of heart attacks. According to the American Heart Association, nearly 400,000 deaths in 2020 are attributable to CHD, and over 800,000 Americans have a heart attack yearly. Cardio Diagnostics’ new patent-pending test, PrecisionCHD, aids in the early detection of coronary heart disease to better enable the management of this condition to prevent a symptomatic event such as a heart attack.

Using epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers along with a proprietary machine-learning model developed by analyzing billions of genomic and epigenomic data points, PrecisionCHD detects coronary heart disease with better than 75% sensitivity in both men and women. A key defining characteristic of PrecisionCHD is its accompanying provider-only Actionable Clinical Intelligence™ platform, which maps a patient’s unique biomarker profile onto modifiable risk factors such as diabetes, hypertension, hypercholesterolemia, and smoking, known to be critical drivers of coronary heart disease.

https://finance.yahoo.com/news/cardio-diagnostics-holdings-inc-launches-130000131.html